Skip to Navigation Skip to Search Skip to Content
Search All Centers

Clinical Trial Combination Therapies

Read Transcript Download/Print Transcript

Published on February 11, 2020

Key Takeaways

  • CAPTIVATE is a clinical trial looking at combining ibrutinib and venetoclax in a multi-center setting. 
  • Findings show that using ibrutinib and venetoclax together may allow patients to not have to continue long-term ibrutinib treatment.

Expert Dr. Matthew Davids, from Dana-Farber Cancer Institute, discusses the CAPTIVATE study, which is looking at the combination of ibrutinib (Imbruvica) and venetoclax (Venclexta) to treat chronic lymphocytic leukemia. Watch as Dr. Davids shares findings from the CLL clinical trial.

This program is sponsored by AbbVie, Inc., Genentech, Inc. and Adaptive Biotechnologies. These organizations have no editorial control. It is produced by Patient Power. Patient Power is solely responsible for program content.

Featuring

You might also like

Transcript | Clinical Trial Combination Therapies

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.

Andrew Schorr:            

Matthew, you want to tell us, CAPTIVATE, they come up with these words, what does it mean? So, tell us about some of these trials and we’ll talk with the others too.

Dr. Davids:                   

Sure. I think the theme right now in CLL is we have so many good treatment options for patients, which is a great thing. And what we’re learning is how to put these together in various ways and whether we even need to put them together in combinations. We don’t know right now whether it’s better to use these drugs together at the same time or to use one at a time in sequence. So, there’s a lot of studies going on right now trying to answer those questions.

Specifically, with the CAPTIVATE study, this is a combination of two of better-known novel drugs, ibrutinib (Imbruvica), which we’ve kind of had the most experience with over the last several years. And venetoclax (Venclexta), which was just recently approved as a first therapy for CLL. So, this is a combination of ibrutinib and venetoclax together.

We’ve seen some data for this in earlier versions. We’ve seen the study from MD Anderson which looked promising. But one of the criticisms was it was just from a single center. So, what would happen if this drug combination was used in a multi-center setting? Meaning lots of different centers from around the study, and that’s what the CAPTIVATE study looked at. 

Andrew Schorr:            

What do we know?

Dr. Davids:                   

It looks very good. So, it actually looks similar to what they had seen at MD Anderson. The majority of patients are getting into very deep remissions. And it raises the prospect of time-limited therapy, so using a combination of the two drugs may allow patients to not have to continue on long-term ibrutinib treatment.

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.

You might also like